A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Recruiting

Phase 1

Phase 2

SPK-10001A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Sponsor:

Hoffmann-La Roche

Code:

NCT06826612

Conditions

Huntington Disease

Eligibility Criteria

Sex: All

Age: 25 - 65

Healthy Volunteers: Not accepted

Interventions

SPK-10001

Placebo Surgery Control

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-13. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-05-05.